Cargando…
Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity
The aggregation of amyloidogenic polypeptides is strongly linked to several neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Conformational antibodies that selectively recognize protein aggregates are leading therapeutic agents for selectively neutralizing toxic aggregate...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081927/ https://www.ncbi.nlm.nih.gov/pubmed/33675750 http://dx.doi.org/10.1016/j.jbc.2021.100508 |
_version_ | 1783685737208610816 |
---|---|
author | Desai, Alec A. Smith, Matthew D. Zhang, Yulei Makowski, Emily K. Gerson, Julia E. Ionescu, Edward Starr, Charles G. Zupancic, Jennifer M. Moore, Shannon J. Sutter, Alexandra B. Ivanova, Magdalena I. Murphy, Geoffrey G. Paulson, Henry L. Tessier, Peter M. |
author_facet | Desai, Alec A. Smith, Matthew D. Zhang, Yulei Makowski, Emily K. Gerson, Julia E. Ionescu, Edward Starr, Charles G. Zupancic, Jennifer M. Moore, Shannon J. Sutter, Alexandra B. Ivanova, Magdalena I. Murphy, Geoffrey G. Paulson, Henry L. Tessier, Peter M. |
author_sort | Desai, Alec A. |
collection | PubMed |
description | The aggregation of amyloidogenic polypeptides is strongly linked to several neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Conformational antibodies that selectively recognize protein aggregates are leading therapeutic agents for selectively neutralizing toxic aggregates, diagnostic and imaging agents for detecting disease, and biomedical reagents for elucidating disease mechanisms. Despite their importance, it is challenging to generate high-quality conformational antibodies in a systematic and site-specific manner due to the properties of protein aggregates (hydrophobic, multivalent, and heterogeneous) and limitations of immunization (uncontrolled antigen presentation and immunodominant epitopes). Toward addressing these challenges, we have developed a systematic directed evolution procedure for affinity maturing antibodies against Alzheimer’s Aβ fibrils and selecting variants with strict conformational and sequence specificity. We first designed a library based on a lead conformational antibody by sampling combinations of amino acids in the antigen-binding site predicted to mediate high antibody specificity. Next, we displayed this library on the surface of yeast, sorted it against Aβ42 aggregates, and identified promising clones using deep sequencing. The resulting antibodies displayed similar or higher affinities than clinical-stage Aβ antibodies (aducanumab and crenezumab). Moreover, the affinity-matured antibodies retained high conformational specificity for Aβ aggregates, as observed for aducanumab and unlike crenezumab. Notably, the affinity-maturated antibodies displayed extremely low levels of nonspecific interactions, as observed for crenezumab and unlike aducanumab. We expect that our systematic methods for generating antibodies with unique combinations of desirable properties will improve the generation of high-quality conformational antibodies specific for diverse types of aggregated conformers. |
format | Online Article Text |
id | pubmed-8081927 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Biochemistry and Molecular Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-80819272021-05-06 Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity Desai, Alec A. Smith, Matthew D. Zhang, Yulei Makowski, Emily K. Gerson, Julia E. Ionescu, Edward Starr, Charles G. Zupancic, Jennifer M. Moore, Shannon J. Sutter, Alexandra B. Ivanova, Magdalena I. Murphy, Geoffrey G. Paulson, Henry L. Tessier, Peter M. J Biol Chem Research Article The aggregation of amyloidogenic polypeptides is strongly linked to several neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Conformational antibodies that selectively recognize protein aggregates are leading therapeutic agents for selectively neutralizing toxic aggregates, diagnostic and imaging agents for detecting disease, and biomedical reagents for elucidating disease mechanisms. Despite their importance, it is challenging to generate high-quality conformational antibodies in a systematic and site-specific manner due to the properties of protein aggregates (hydrophobic, multivalent, and heterogeneous) and limitations of immunization (uncontrolled antigen presentation and immunodominant epitopes). Toward addressing these challenges, we have developed a systematic directed evolution procedure for affinity maturing antibodies against Alzheimer’s Aβ fibrils and selecting variants with strict conformational and sequence specificity. We first designed a library based on a lead conformational antibody by sampling combinations of amino acids in the antigen-binding site predicted to mediate high antibody specificity. Next, we displayed this library on the surface of yeast, sorted it against Aβ42 aggregates, and identified promising clones using deep sequencing. The resulting antibodies displayed similar or higher affinities than clinical-stage Aβ antibodies (aducanumab and crenezumab). Moreover, the affinity-matured antibodies retained high conformational specificity for Aβ aggregates, as observed for aducanumab and unlike crenezumab. Notably, the affinity-maturated antibodies displayed extremely low levels of nonspecific interactions, as observed for crenezumab and unlike aducanumab. We expect that our systematic methods for generating antibodies with unique combinations of desirable properties will improve the generation of high-quality conformational antibodies specific for diverse types of aggregated conformers. American Society for Biochemistry and Molecular Biology 2021-03-04 /pmc/articles/PMC8081927/ /pubmed/33675750 http://dx.doi.org/10.1016/j.jbc.2021.100508 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Article Desai, Alec A. Smith, Matthew D. Zhang, Yulei Makowski, Emily K. Gerson, Julia E. Ionescu, Edward Starr, Charles G. Zupancic, Jennifer M. Moore, Shannon J. Sutter, Alexandra B. Ivanova, Magdalena I. Murphy, Geoffrey G. Paulson, Henry L. Tessier, Peter M. Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity |
title | Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity |
title_full | Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity |
title_fullStr | Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity |
title_full_unstemmed | Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity |
title_short | Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity |
title_sort | rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081927/ https://www.ncbi.nlm.nih.gov/pubmed/33675750 http://dx.doi.org/10.1016/j.jbc.2021.100508 |
work_keys_str_mv | AT desaialeca rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity AT smithmatthewd rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity AT zhangyulei rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity AT makowskiemilyk rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity AT gersonjuliae rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity AT ionescuedward rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity AT starrcharlesg rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity AT zupancicjenniferm rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity AT mooreshannonj rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity AT sutteralexandrab rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity AT ivanovamagdalenai rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity AT murphygeoffreyg rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity AT paulsonhenryl rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity AT tessierpeterm rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity |